Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
41
Journal Issue
26
Date Issued
2023-09-10
Author(s)
Piotrowska, Zofia
Tan, Daniel Shao-Weng
Smit, Egbert F
Spira, Alexander I
Soo, Ross A
Nguyen, Danny
Lee, Victor Ho-Fun
Velcheti, Vamsidhar
Wrangle, John M
Socinski, Mark A
Koczywas, Marianna
Janik, John E
Jones, Jeffrey
Yu, Helena Alexandra
Abstract
Although several agents targeting epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) have recently been approved by the US Food and Drug Administration, toxicities related to the inhibition of wild-type (WT) EGFR are common with these agents and affect overall tolerability. Zipalertinib (CLN-081, TAS6417) is an oral EGFR tyrosine kinase inhibitor (TKI) with a novel pyrrolopyrimidine scaffold leading to enhanced selectivity for EGFR ex20ins-mutant versus WT EGFR with potent inhibition of cell growth in EGFR ex20ins-positive cell lines.
SDGs
Type
journal article